<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02091973</url>
  </required_header>
  <id_info>
    <org_study_id>WWC-004</org_study_id>
    <nct_id>NCT02091973</nct_id>
  </id_info>
  <brief_title>MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation</brief_title>
  <official_title>MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Maintenance Immunosuppressive Regimens in Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The calcineurin inhibitor drugs including cyclosporin and tacrolimus are well-known as
      nephrotoxicity. However, these drugs are essential for kidney transplant especially in high
      immunological risks. To date, however, there is an alternative regimen by using of
      everolimus-based which showing less toxicity than tacrolimus-based regimen by its mechanisms.
      Of note, this study aims to evaluate the toxicity by using microRNA profiles detection
      between everolimus-based and tacrolimus-based immunosuppressive regimen in kidney
      transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The author aims to evaluate the effects of two regimens (everolimus-based versus
      tacrolimus-based) in kidney transplantation recipients. Both of regimens are prescribed only
      in recipents who have low immunologicla risks. After informed consent, all eligible
      recipients will be collected blood and urine sample for microRNA profile testing during study
      periods.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>microRNA profiles</measure>
    <time_frame>5 years</time_frame>
    <description>microRNA profiles including rejection and nephrotoxicity markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Allograft tissue pathology</measure>
    <time_frame>At year 2 and 5</time_frame>
    <description>Pathology studies including rejection, interstitial fibrosis and tubular atrophy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>microRNA Profiles</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus dosing to tough level 6-10 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus dosing to target tough level 5-10 ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus dosing to target tough level 6-10 mg/ml</description>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus dosing to target tough level 5-10 ng/ml</description>
    <arm_group_label>Tacrolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have given informed consent to participate in the study

          -  Actual eGFR &gt; 20-25 ml/min/1.73 m2

        Exclusion Criteria:

          -  Multi-organ transplantation

          -  Pregnancy

          -  ABO incompatible blood group

          -  Second, third, fouth kidney transplantation

          -  HIV positive, active or carrier in any infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wiwat Chancharoenthana, MD, Msc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wiwat Chancharoenthana, MD, MSc.</last_name>
    <phone>6622564251</phone>
    <phone_ext>101</phone_ext>
    <email>wiwatmd@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wiwat Chancharoenthana, MD, MSc</last_name>
      <phone>6622564251</phone>
      <phone_ext>106</phone_ext>
      <email>wiwatmd@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Wiwat Chancharoenthana</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>everolimus</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>microRNA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

